View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Catalent
29 November 2016

Catalent Acquires Accucaps to Expand Softigel Development and Manufacturing

Global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products Catalent has announced that the company has agreed to acquire Accucaps Industries, the Canada-based developer and manufacturer of over-the-counter (OTC), high-potency, and conventional pharmaceutical softgels.

The acquisition is subject to Canadian Governmental approval and financial details of the transaction have not been disclosed.

It will substantially complement Catalent’s global OTC and prescription pharmaceutical softgel capabilities with the addition of a portfolio of products supplied to pharmaceutical companies in North America and two state-of-the-art facilities offering integrated softgel development, manufacturing, and packaging. This will strengthen Catalent’s ability to offer customers turnkey solutions.

Commenting on the acquisition, Catalent’s president of softgel technologies Dr. Aris Gennadios said: "Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments."

Upon completion of the acquisition, more than 500 Accucaps’ employees at its two facilities in Windsor and Strathroy will join Catalent’s global network of 11 softgel technologies facilities.

The Accucaps facilities house sizeable blistering, bottling, and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise.

Catalent’s RP Scherer Softgel is a global leader in innovative oral and topical softgel technologies for the pharmaceutical, consumer health, and cosmetics markets. Its softgel technologies are proven to solve complex bioavailability and formulation challenges, and are preferred in a wide range of consumer health and pharmaceutical product categories.

Catalent leverages more than 80 years of experience in softgel formulation, development, and manufacturing, as well as its proactively developed products to help customers bring products to market faster.

With a variety of unique, innovative technologies, and highly versatile, most preferred dose forms, Catalent has a wide variety of solutions to meet its customers’ needs.

Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.
Catalent Pharma provided London-based pharmaceutical company Trio Medicines with three formulation technologies and four prototypes showing improved solubility and bioavailability for an acetyl prodrug of...
With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to...
The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology